Drug Overview

The Globo H DT Vaccine OBI-833 is a cutting-edge cancer vaccine designed to help the body’s immune system fight various types of epithelial tumors. In the medical world, this is known as a Targeted Immunotherapy. Unlike standard vaccines that prevent diseases like the flu, this is a “therapeutic vaccine,” meaning it is used to treat a person who already has cancer by teaching their immune system to recognize and kill tumor cells.

This vaccine is considered a “Smart Drug” because it targets a very specific sugar molecule found on the surface of many cancer cells but rarely on healthy cells. By focusing on this unique marker, the vaccine aims to destroy the cancer while leaving healthy parts of the body alone.

Generic Name: OBI-833 (Globo H-Diphtheria Toxoid vaccine)
US Brand Names: None (Currently an investigational drug)
Drug Class: Cancer Vaccine; Active Immunotherapy; Glycoconjugate Vaccine
Route of Administration: Subcutaneous (Injection under the skin)
FDA Approval Status: Investigational (Currently in Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how OBI-833 works, imagine a cancer cell is wearing a specific “disguise” or marker. This marker is a complex sugar called Globo H. Globo H is found in high amounts on the surface of breast, lung, gastric, and pancreatic cancer cells.

At the molecular level, OBI-833 works through a “Tag and Attack” process:

The Tag (Globo H): The vaccine contains the Globo H sugar molecule. However, since the immune system doesn’t always notice sugar on its own, scientists have attached it to a carrier protein called Diphtheria Toxoid (DT).
The Wake-Up Call: When the vaccine is injected, the Diphtheria Toxoid acts like a loud alarm. It alerts the immune system to the presence of the Globo H sugar.
B-Cell Activation: Specialized immune cells called B-cells see this “Globo H-DT” combination and begin to produce Antibodies (IgG and IgM). These antibodies are like heat-seeking missiles programmed to find the Globo H sugar.
The Attack: These antibodies travel through the blood and stick to any cancer cell that has Globo H on its surface. Once attached, they call in other immune soldiers (like Natural Killer cells and Macrophages) to destroy the tumor cell.
Memory: The goal is for the immune system to “remember” this sugar, so it can keep fighting any new cancer cells that might appear later.

FDA Approved Clinical Indications

As an investigational drug, OBI-833 is currently only available to patients enrolled in approved clinical trials. It is not yet approved for general use.

Oncological Uses (Investigational)

Non-Small Cell Lung Cancer (NSCLC): Being studied as a maintenance therapy.
Gastric Cancer: Investigated for use in advanced or metastatic stomach cancer.
Breast Cancer: Researched for its ability to prevent cancer from returning.
Pancreatic Cancer: Studied in combination with other immunotherapies.

Non-Oncological Uses

There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

OBI-833 is given as a series of injections. It is usually combined with an “adjuvant” called OBI-821 (a substance that makes the vaccine work better).

Protocol Detail	Standard Investigational Guidance
Standard Dose	Often 30 µg to 100 µg of the Globo H-DT conjugate.
Route	Subcutaneous (Injection just under the skin).
Frequency	Weekly “Priming” for 4 weeks; then monthly “Boosters.”
Administration Time	A quick injection, usually less than 2 minutes.

Dose Adjustments:

Renal/Hepatic Insufficiency: Because this is a biological vaccine and not a chemical drug processed by the liver or kidneys, specific dose adjustments for organ failure are generally not required.

Clinical Efficacy and Research Results

Clinical data from 2020–2025 has shown that OBI-833 is safe and can create a strong immune response in patients with advanced cancers.

Immune Response: In early-phase trials for lung and gastric cancer, numerical data showed that over 80% of patients developed high levels of anti-Globo H antibodies after the fourth injection.
Progression-Free Survival: In maintenance studies for lung cancer, researchers found that patients who produced the most antibodies lived longer without their disease getting worse.
Numerical Trends: While larger survival rates are still being gathered, early results suggest that the vaccine can delay disease progression by several months in certain high-responding patients.

Safety Profile and Side Effects

OBI-833 is generally much “gentler” than traditional chemotherapy because it targets a specific sugar rather than attacking all fast-growing cells.

Black Box Warning:

None. (Investigational vaccines do not yet have formal Black Box Warnings).

Common Side Effects (>10%)

Injection Site Reaction: Redness, swelling, or a small bump where the needle went in.
Fatigue: Feeling unusually tired.
Flu-like Symptoms: Mild fever, chills, or muscle aches shortly after the injection.

Serious Adverse Events

Severe Allergic Reaction: Rare but possible (Anaphylaxis).
Autoimmune Response: A very rare situation where the immune system becomes too active and attacks healthy tissue.

Management Strategies

For Site Pain: Use a cold compress on the injection area.
For Fever/Aches: Standard over-the-counter fever reducers (like Acetaminophen) are usually sufficient.

Research Areas

OBI-833 is a key part of Immunotherapy research. Scientists are currently testing if it works better when combined with “Checkpoint Inhibitors” (like Keytruda). While OBI-833 “points out” the cancer to the immune system, Checkpoint Inhibitors “take the brakes off” the immune system so it can attack more aggressively. There is also early research into using the Globo H marker to help Stem Cell therapies better identify and avoid cancer cells during regenerative treatments.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Globo H Testing: A biopsy of the tumor may be tested to see if it has the Globo H sugar.
Baseline Antibody Check: To see the starting levels of your immune response.
Blood Panel: A general check of your white blood cells and immune health.

Precautions During Treatment

Immune Suppression: If you are taking high-dose steroids, the vaccine may not work as well. Talk to your doctor before starting.
Skin Care: Do not apply creams or lotions to the injection site for 24 hours.

“Do’s and Don’ts” List

Do stay hydrated and rest on the day of your injection.
Do report any high fever or sudden trouble breathing to your team immediately.
Don’t skip your “booster” shots, as the immune system needs constant reminders to stay alert.
Don’t assume the “bump” at the injection site is an infection; it is usually a sign that your immune system is “waking up.”

Legal Disclaimer

Standard Medical Information Disclaimer: This guide is for informational purposes only and does not constitute medical advice. OBI-833 is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. This information is based on medical data available as of March 2026.